GlaxoSmithKline
GSK
NZ$62.71
Share price
-1.37%
Change (1 day)
-7.88%
Change (1 year)
Categories
P/S ratio for GlaxoSmithKline (GSK)
P/S ratio as of July 2025 (TTM): 1.86
According to GlaxoSmithKline's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.29. At the end of 2025 the company had a P/S ratio of 1.94.
P/S ratio history for GlaxoSmithKline from 2001 to 2025
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2025 | 1.94 | 12.16% |
| 2024 | 1.73 | -13.98% |
| 2023 | 2.01 | -0.68% |
| 2022 | 2.03 | -25.58% |
| 2021 | 2.72 | 29.93% |
| 2020 | 2.09 | -22.44% |
| 2019 | 2.70 | 17.16% |
| 2018 | 2.31 | 3.63% |
| 2017 | 2.22 | -13.14% |
| 2016 | 2.56 | -6.53% |
| 2015 | 2.74 | -0.96% |
| 2014 | 2.77 | -10.31% |
| 2013 | 3.08 | 23.29% |
| 2012 | 2.50 | -6% |
| 2011 | 2.66 | 14.19% |
| 2010 | 2.33 | -4.89% |
| 2009 | 2.45 | 10.66% |
| 2008 | 2.21 | -27.5% |
| 2007 | 3.05 | -13.74% |
| 2006 | 3.54 | -7.33% |
| 2005 | 3.82 | 2.31% |
| 2004 | 3.73 | 1.44% |
| 2003 | 3.68 | 6.04% |
| 2002 | 3.47 | -33.3% |
| 2001 | 5.21 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 AstraZeneca AZN | 4.13 | 121.60% | 🇬🇧 UK |
 Pfizer PFE | 2.21 | 18.79% | 🇺🇸 USA |
 Merck MRK | 3.30 | 77.27% | 🇺🇸 USA |
 Novartis NVS | 4.23 | 126.86% | 🇨🇭 Switzerland |
 Sanofi SNY | 2.54 | 36.42% | 🇫🇷 France |
 Teva Pharmaceutical Industries TEVA | 1.14 | -38.82% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | 4.60 | 147.03% | 🇺🇸 USA |